The results showed that the expression levels of CDH2, SNAI1, ZEB1, and ZEB2 were significantly downregulated in prostate cancer compared to controls, while the expression of CDH1 was significantly upregulated (Figure 8). This evidence concerns the gene CDH2 and prostate carcinoma.